Adenovirus carrying TIMP-3: A potential tool for cervical cancer treatment

Gynecologic Oncology

Volumn 108, Issue 1, 2008, Pages 234-240

  Zhang, Ying ^a,b   Qian, Haili ^a   Lin, Chen ^a   Lang, Jinghe ^a   Xiang, Yang ^a   Fu, Ming ^a   Zhang, Xueyan ^a   Liang, Xiao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus vector; Cervical cancer; Gene therapy; TIMP 3

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL BASED GENE THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL KILLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS INFECTIONS, HUMAN; ANIMALS; APOPTOSIS; CELL DIVISION; CELL GROWTH PROCESSES; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; G2 PHASE; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; MICE; MICE, NUDE; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 37449004394     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.09.033     Document Type: Article

References (53)

1. Freije J., Balbin M., Pendas A.M., Sanchez L.M., Puente X.S., and Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 532 (2003) 91-107
2. John A., and Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7 (2001) 14-23
3. Westermarck J., and Kaharl V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13 (1999) 781-792
4. Sheu B.C., Lien H.C., Ho H.N., Lin H.H., Chow S.N., Huang S.C., et al. Increased expression and activation of gelatinolytic matrix metalloproteinase is associated with the progression and recurrence of human cervical cancer. Cancer Res 63 (2003) 6537-6542
5. Noriyuki M., Sumi T., Zhi X., Misugi F., Nobeyama H., et al. Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women. Int J Oncol 31 (2007) 531-536
6. Sier C.F., Zuidwijk K., Zijlmans H.J., Hanemaaijer R., Mulder-Stapel A.A., Prins F.A., et al. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. Int J Cancer 118 (2006) 2991-2998
7. Curran S., and Murray G.I. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36 (2000) 1621-1630
8. Brinckerhoff C.E., and Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3 (2002) 207-214
9. Jiang Y., Goldberg I.D., and Shi Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21 (2002) 2245-2252
10. Yana I., and Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 19 (2002) 209-215
11. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors:biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719-3727
12. Leeman M.F., Curran S., and Murray G.I. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201 (2003) 528-534
13. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
14. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
15. Hidalgo M., and Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93 (2001) 178-193
16. Yu W.H., Yu S., Meng Q., Brew K., and Woessner Jr. J.F. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 275 (2000) 31226-31232
17. Apte S.S., Olsen B.R., and Murphy G. The gene structure of tissue inhibitor of metalloproteinases(TIMP-3) and its inhibitory activites define the distinct TIMP gene family. J Bio Chem 270 (1995) 14313-14318
18. Leco K.J., Khokha R., Pavloff N., Hawkes S.P., and Edwards D.R. Tissue inhibitor of -3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269 (1994) 9352-9360
19. Baker A.H., Zaltsman A.B., George S.J., and Newby A.C. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101 (1998) 1478-1487
20. Baker A.H., George S.J., Zaltsman A.B., Murphy G., and Newby A.C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79 (1999) 347-1355
21. Ahonen M., Ala-Aho R., Baker A.H., et al. Antitumor activity and bystanderer effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 5 (2002) 705-715
22. Ma D.H., Chen J.I., Zhang F., Hwang D.G., and Chen J.K. Inhibition of fibroblast-induced angiogenic phenotype of cultured endothelial cells by the overexpression of tissue inhibitor of metalloproteinase (TIMP)-3. J Biomed Sci 10 (2003) 526-534
23. Yang H.J., Liu V.W., Wang Y., Tsang P.C., and Ngan H.Y. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 23 (2006) [6:212]
24. Wild A., Ramaswamy A., Langer P., Celik I., Fendrich V., and Chaloupka B. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J Clin Endocrinol Metab 88 (2003) 1367-1373
25. He T.C., Zhou S., da Costa L.T., et al. A simplified system for generation recombinant adenovirus [J]. Proc Natl Acad Sci U S A 95 (1998) 2509-2514
26. Uzunoglu S., Uslu R., Tobu M., Saydam G., Terzioglu E., Buyukkececi F., et al. Exit from G2 phase after 2 Gy gamma irradiation is faster in radiosensitive human cells with high expression of the RAF1 proto-oncogene. Radiat Res 146 (1996) 485-493
27. Berenbaum M.C. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35 (1981) 269-335
28. Inoue A., Narumi K., Matsubara N., Sugawara S., Saijo Y., Satoh K., et al. Administration of wild-type P53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of P53 gene. Cancer Lett 157 (2000) 105-112
29. Sato T., Sakai T., Noguchi Y., Takita M., Hirakawa S., and Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92 (2004) 47-56
30. Rauvala M., Aglund K., Puistola U., Turpeenniemi-Hujanen T., Horvath G., Willen R., et al. Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer 16 (2006) 1297-1302
31. Mitra A., Chakrabarti J., Chattopadhyay N., and Chatterjee A. Membrane-associated MMP-2 in human cervical cancer. J Environ Pathol Toxicol Oncol 22 (2003) 93-100
32. Branca M., Ciotti M., Giorgi C., Santini D., Di Bonito L., Costa S., et al. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. Anticancer Res 26 (2006) 1543-1556
33. Lizarraga F., Espinosa M., Maldonado V., and Melendez-Zajgla J. Tissue inhibitor of metalloproteinases-4 is expressed in cervical cancer patients. Anticancer Res 25 (2005) 623-627
34. Jeong D.H., Youm M.Y., Kim Y.N., Lee K.B., Sung M.S., Yoon H.K., et al. Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer 6 (2006) 1234-1240
35. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 14 (2000) 163-176
36. Manes S., Mira E., Barbacid M.M., Cipres A., Fernandez-Resa P., Buesa J.M., et al. Identification of insulinlike growth factor-binding protein-1 as a potential physiologic substrate for human stromelysin-3. J Biol Chem 272 (1997) 25706-25712
37. Manes S., Llorente M., Lacalle R.A., Gomez-Moutón C., Kremer L., Mira E., et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274 (1999) 6935-6945
38. Kashiwagi M., Tortorella M., Nagase H., Brew K., et al. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 276 (2001) 12501-12504
39. Smith M.R., Kung H., Durum S.K., Colburn N.H., and Sun Y. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 9 (1997) 770-780
40. Fitzgerald M.L., Wang Z., Park P.W., Murphy G., and Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148 (2000) 811-824
41. Rigg A.S., and Lemoine NR. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 8 (2001) 869-878
42. Baker A.H., George S.J., Zaltsman A.B., Murphy G., and Newby A.C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79 (1999) 1347-1355
43. Spurbeck W.W., Ng C.Y., Strom T.S., Vanin E.F., and Davidoff A.M. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 100 (2002) 3361-3368
44. Tran P.L., Vigneron J.P., Pericat D., Dubois S., Cazals D., Hervy M., et al. Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Ther 10 (2003) 435-444
45. Lamfers M.L., Gianni D., Tung C.H., Idema S., Schagen F.H., Carette J.E., et al. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res 65 (2005) 9398-9405
46. Shilitoe E.J., Kamath P., and Chen Z. Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther 1 (1994) 193-204
47. Brinton L.A. The epidemiology of human papillomavirus and cervical cancer. IARC Sci Publ Lyon 119 (1992) 3-23
48. Song S., Pitot H.C., and Lambert P.F. The human papillomavivus type 16 E6 alone is sufficient to induce carcinomas in tuansgenic animals. J Virol 73 (1999) 5887-5893
49. Ahn W.S., Bae S.M., Lee J.M., Namkoong S.E., Yoo J.Y., Seo Y.S., et al. Anti-cancer effect of adenovirus p53 on human cervical cancer cell growth in vitro and in vivo. Int J Gynecol Cancer 14 (2004) 322-332
50. Horio Y., Hasegawa Y., Sekido Y., et al. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivy of nonsmall cell cancer cells. Cancer Gene Ther 7 (2000) 537-544
51. Hornback N.B., Shen R.N., Sutton G.P., and Belli M. Synergistic cytotoxic and antitumor effects of irradiation and taxol on human HeLa cervix carcinoma and mouse B16 melanoma cells. In Vivo 8 (1994) 819-823
52. Belli M., Sapora O., and Tabocclini M.A. Molecular targets in cellular response to ionizing radiation and implications in space radiation protection [J]. Radiat Res (Tokyo) 43 (2002) 13-519
53. McKenna W.G., Weiss M.C., Endlich B., Ling C.C., Bakanauskas V.J., Kelsten M.L., et al. Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50 (1990) 97-102